Transforming PCI Informed Consent Into an Evidence-based Decision-making Tool (PRISM)

This study has been completed.
Sponsor:
Collaborators:
Washington University School of Medicine
Baylor Research Institute
Baystate Medical Center
Henry Ford Health System
Kaiser Permanente
Prairie Education and Research Cooperative
Information provided by:
Saint Luke's Health System
ClinicalTrials.gov Identifier:
NCT01383382
First received: June 27, 2011
Last updated: September 7, 2012
Last verified: June 2011
  Purpose

Using individualized patient estimates of procedural risks and benefits, this project will transform the process of informed consent for coronary angioplasty into a dynamic educational tool for patients and physicians and is a direct response to the Institute of Medicine's call for a more evidence‐based, efficient, patient‐centered healthcare system. It is hypothesized that patients will develop a greater understanding of their individual risks and benefits from PCI, will be empowered to more actively engage in shared decision-making, as well as have improved awareness of their responsibility to adhere to dual anti-platelet therapy if treated with a drug eluting stent (risks for target vessel revascularization with bare metal and drug eluting stents are also provided in the new consent form). It is also anticipated that physicians, in turn, will use these individualized estimates to better discriminate between risks and benefits among different bleeding avoidance therapies so as to improve the safety and cost-effectiveness of PCI.


Condition
Non-emergent Percutaneous Coronary Intervention (PCI)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Transforming PCI Informed Consent Into an Evidence-based Decision-making Tool

Further study details as provided by Saint Luke's Health System:

Enrollment: 1399
Study Start Date: September 2009
Study Completion Date: September 2012
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Detailed Description:

This study will test the impact of a new mechanism for eliciting informed consent from patients undergoing percutaneous coronary intervention (PCI) on 1) patients' comprehension of procedural risks/benefits and participation in shared decision-making; and 2) upon clinicians' use of effective strategies to minimize the risk of bleeding at the time of PCI. To facilitate these goals, we will prospectively provide each patients' risks for bleeding at the time that the informed consent document is generated. This will be accomplished by transforming the infrastructure of the informed consent process at participating study centers using a novel, web‐based system - the Personalized Risk Information Services Manager (PRISM) - to generate individualized consent forms with estimates of risks and outcomes using validated multivariable models from the American College of Cardiology's NCDR. The goals of this study are to 1) identify barriers in implementing individualized consent forms in clinical care and to test whether this novel consent process 2) improves the quality of the informed consent process, 3) supports the more rational use of Bleeding Avoidance Therapies (BATs), 4) reduces bleeding events after PCI, and 5) supports a more cost-effective PCI procedure. This will be done using a pre-post design at 6 enrolling hospitals and comparing changes in practice with contemporaneous controls matched from the broader NCDR Cath/PCI registry.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Cardiac patients undergoing a non-emergent percutaneous coronary intervention (PCI) procedure for their heart disease.

Criteria

Inclusion Criteria:

  • All patients receiving a PCI in a participating institution

Exclusion Criteria:

  • Previously enrolled in the PRISM
  • Does not speak English or Spanish
  • Dementia
  • Too ill to interview
  • Current prisoner
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01383382

Locations
United States, California
Kaiser Permanente
Oakland, California, United States, 94612
United States, Illinois
Prairie Education and Research Cooperative
Springfield, Illinois, United States, 62701
United States, Massachusetts
Baystate Medical Center
Springfield, Massachusetts, United States, 01199
United States, Michigan
Henry Ford Health System
Detroit, Michigan, United States, 48202
United States, Missouri
Saint Luke's Hospital of Kansas City
Kansas City, Missouri, United States, 64111
Barnes-Jewish Hospital/Washington University School of Medicine
St. Louis, Missouri, United States, 63130
United States, Texas
Baylor Research Institute
Plano, Texas, United States, 75204
Sponsors and Collaborators
Saint Luke's Health System
Washington University School of Medicine
Baylor Research Institute
Baystate Medical Center
Henry Ford Health System
Kaiser Permanente
Prairie Education and Research Cooperative
Investigators
Principal Investigator: John A Spertus, MD, MPH Saint Luke's Hospital of Kansas City
  More Information

No publications provided

Responsible Party: John A. Spertus, MD, MPH, Saint Luke's Hospital of Kansas City
ClinicalTrials.gov Identifier: NCT01383382     History of Changes
Other Study ID Numbers: R01HL096624
Study First Received: June 27, 2011
Last Updated: September 7, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Saint Luke's Health System:
Heart Diseases
Cardiovascular Diseases
Acute Myocardial Infarction
Decision Making
Percutaneous Coronary Intervention
Informed Consent
Quality of Care

ClinicalTrials.gov processed this record on May 23, 2013